ARMA (Anti-Reflux Mucosal Ablation) for GERD

ARMA (Anti-Reflux Mucosal Ablation) is a minimally invasive endoscopic procedure that treats GERD by working with the body's own anatomy rather than adding anything artificial. It's performed entirely through the mouth, with no external incisions, positioning it between medication and surgery for patients who need more than PPIs but want to avoid a surgical fundoplication.

In short: yes, for the right patients, and the results are well supported. About 8 to 9 out of 10 patients achieve lasting symptom control after ARMA, and among those followed for two years or longer, roughly 3 out of 4 still have good results. Most patients are able to reduce or stop regular reflux medication afterward. The most common side effect is mild, temporary difficulty swallowing in the first couple of weeks while the treated area heals — serious complications are uncommon. The section further down this page, ‘The evidence in more detail,’ walks through the specific studies behind these numbers for anyone who wants that level of detail; the short version is that ARMA has one of the more consistent, well-supported evidence bases among the endoscopic options for GERD.

The lower esophageal sphincter and surrounding tissue at the gastroesophageal junction form a natural flap valve that normally prevents stomach contents from moving back up. In GERD, this valve mechanism is often weakened or doesn't close properly. ARMA uses a specialized endoscopic tool to precisely ablate the mucosa at this junction in a controlled pattern. As the treated tissue heals, it forms scar tissue that tightens and reshapes the flap valve, mechanically improving its ability to prevent reflux — a different approach from medication, which reduces acid but doesn't fix the underlying valve weakness.

• Confirmed GERD, diagnosed through upper GI endoscopy and pH monitoring — not assumed from symptoms alone
• PPI-dependent GERD (symptoms well-controlled on medication, but the patient wants to avoid long-term reliance on it) or PPI-refractory GERD (symptoms persisting despite medication)
• Patients who prefer to avoid surgical fundoplication, or aren't ideal candidates for it
• A hiatal hernia is present in most patients who undergo ARMA — see the Hiatal Hernia page for that connection
• Generally not appropriate for patients with severe esophagitis, Barrett's esophagus, a large hiatal hernia (over 2cm), significant esophageal motility disorders, or those who've already had anti-reflux surgery — pre-procedure evaluation determines suitability

• Before: upper GI endoscopy and esophageal manometry to confirm the diagnosis and rule out conditions that would make ARMA inappropriate
• During: performed under sedation, taking approximately 40 minutes
• After: a short course of PPI medication, typically 4–6 weeks, to support healing
• Follow-up: review at around 2 weeks to check early healing, then again at 2–3 months to assess symptom response

Note: evidence for GERDx specifically is more mixed than for ARMA — a sham-controlled trial did not show clear objective benefit over sham, and longer-term follow-up shows a substantial proportion of patients eventually need conversion to surgery. See the GERDx page for the full picture before presenting it as an equivalent alternative to ARMA.

ARMA's effect is mechanical — it reinforces the valve itself — but ongoing lifestyle factors (weight, diet, meal timing) still influence overall reflux control, the same way they do for anyone managing GERD.

This section is for anyone who wants the specific research behind the numbers above — it's not necessary reading to understand whether ARMA is right for you, but it's here for transparency.

A 2024 bi-center study found that median GERD-related quality of life scores improved from 26 to 11 at six months following ARMA — a statistically significant and clinically meaningful reduction in symptom burden. The same data showed acid exposure time falling from 5.3% to 0.7%, indicating a genuine reduction in reflux, not just a subjective improvement in reported symptoms. At longer follow-up, published data shows 75–80% of patients maintain stable symptom relief at two years or more, with occasional mild recurrence typically manageable with a short course of PPIs or, in some cases, a repeat ablation. Compared with ARMS (a related mucosal-removal technique), the ablation-based approach in ARMA carries a lower risk of circumferential scarring and swallowing difficulty while achieving equivalent reflux control, per published systematic review data.

ARMA is one of several endoscopic answers to reflux, and the right one depends on your anatomy and on how the reflux actually behaves — GERDx and TIF address the same problem by different means. Our gastroenterologists assess candidacy with endoscopy, pH monitoring, and manometry before recommending any of them. To find out whether ARMA is suitable for you, book a consultation.